Showing results (121-130 of 689) with videos related to
Sort By:
Pageof 69
Current Medicinal Chemistry|February 10, 2009
Current status of newer carbapenemsMatteo Bassetti, Laura Nicolini, Silvano Esposito, et al.Current Opinion in Infectious Diseases|February 19, 2020
Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infectionsMatteo Bassetti, Laura Magnasco, Filippo Del Puente, et al.The Journal of Antimicrobial Chemotherapy|February 7, 2017
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)Michael A Pfaller, Matteo Bassetti, Leonard R Duncan, et al.Expert Review of Anti-Infective Therapy|December 21, 2012
Epidemiology, diagnosis and treatment of Clostridium difficile infectionMatteo Bassetti, Giovanni Villa, Davide Pecori, et al.Expert Opinion on Investigational Drugs|April 2, 2009
The role of telavancin in the treatment of MRSA infections in hospitalMatteo Bassetti, Malgorzata Mikulska, Elda Righi, et al.Annals of Intensive Care|April 20, 2016
Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientMatteo Bassetti, Charles-Edouard Luyt, David P Nicolau, et al.Current Opinion in Infectious Diseases|January 17, 2018
New antibiotics for ventilator-associated pneumoniaMatteo Bassetti, Antionio Vena, Nadia Castaldo, et al.Current Opinion in Infectious Diseases|February 11, 2026
Tropical infectious diseases and skin manifestations: a diagnostic frameworkGaia Cologgi, Marianna Giurco, Rebecca Donadoni, et al.Infection and Drug Resistance|April 27, 2026
Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative InfectionsMonica Melchio, Federica Briano, Chiara Sepulcri, et al.The Journal of Antimicrobial Chemotherapy|October 18, 2003
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adultsJavier Garau, Monique Twynholm, Elena Garcia-Mendez, et al.Pageof 69